JP5727944B2 - 改良プロセス - Google Patents

改良プロセス Download PDF

Info

Publication number
JP5727944B2
JP5727944B2 JP2011552515A JP2011552515A JP5727944B2 JP 5727944 B2 JP5727944 B2 JP 5727944B2 JP 2011552515 A JP2011552515 A JP 2011552515A JP 2011552515 A JP2011552515 A JP 2011552515A JP 5727944 B2 JP5727944 B2 JP 5727944B2
Authority
JP
Japan
Prior art keywords
lenalidomide
solvent system
process according
nitro
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011552515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519207A (ja
JP2012519207A5 (enExample
Inventor
ゴレ，ビナーヤク・ゴビンド
シュクラ，ビナイ・クマール
バンダリ，シュレヤス・シュリカント
ハスベ，スレシュ
Original Assignee
ジェネリクス・［ユーケー］・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネリクス・［ユーケー］・リミテッド filed Critical ジェネリクス・［ユーケー］・リミテッド
Publication of JP2012519207A publication Critical patent/JP2012519207A/ja
Publication of JP2012519207A5 publication Critical patent/JP2012519207A5/ja
Application granted granted Critical
Publication of JP5727944B2 publication Critical patent/JP5727944B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Optical Communication System (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
JP2011552515A 2009-03-02 2010-03-01 改良プロセス Expired - Fee Related JP5727944B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN383KO2009 2009-03-02
IN383/KOL/2009 2009-03-02
IN463/KOL/2009 2009-03-16
IN463KO2009 2009-03-16
PCT/GB2010/050352 WO2010100476A2 (en) 2009-03-02 2010-03-01 Improved process

Publications (3)

Publication Number Publication Date
JP2012519207A JP2012519207A (ja) 2012-08-23
JP2012519207A5 JP2012519207A5 (enExample) 2013-04-18
JP5727944B2 true JP5727944B2 (ja) 2015-06-03

Family

ID=54290149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011552515A Expired - Fee Related JP5727944B2 (ja) 2009-03-02 2010-03-01 改良プロセス

Country Status (16)

Country Link
US (1) US8946265B2 (enExample)
EP (1) EP2403845B1 (enExample)
JP (1) JP5727944B2 (enExample)
CN (1) CN102414196A (enExample)
AU (1) AU2010220204B2 (enExample)
CA (1) CA2753241C (enExample)
CY (1) CY1115376T1 (enExample)
DK (1) DK2403845T3 (enExample)
ES (1) ES2487215T3 (enExample)
HR (1) HRP20140686T1 (enExample)
NZ (1) NZ595492A (enExample)
PL (1) PL2403845T3 (enExample)
PT (1) PT2403845E (enExample)
SI (1) SI2403845T1 (enExample)
SM (1) SMT201400100B (enExample)
WO (1) WO2010100476A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
ES2727705T3 (es) 2010-03-08 2019-10-18 Natco Pharma Ltd Forma I de lenalidomida anhidra
MX352824B (es) 2010-06-16 2017-12-11 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
WO2013012485A2 (en) 2011-07-19 2013-01-24 Amplio Pharma, Llc Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
EP2968309A4 (en) 2013-03-13 2016-08-31 Inflammatory Response Res Inc USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US9808450B2 (en) 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
US20170107193A1 (en) * 2014-04-26 2017-04-20 Shilpa Medicare Limited Crystalline lenalidomide process
US10392364B2 (en) 2014-08-11 2019-08-27 Avra Laboratories Pvt. Ltd. Process for synthesis of lenalidomide
WO2016026785A1 (en) * 2014-08-19 2016-02-25 Synthon B.V. Process for making crystalline form a of lenalidomide
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
EP3393457A1 (en) * 2015-12-22 2018-10-31 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
JP2020535192A (ja) * 2017-09-27 2020-12-03 バイオコン・リミテッド レナリドミドの結晶形
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN111196800B (zh) * 2018-11-19 2022-10-11 欣凯医药化工中间体（上海）有限公司 一种制备来那度胺的方法
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
ES2437592T3 (es) 2004-09-03 2014-01-13 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
AU2008240078B2 (en) 2007-04-16 2012-10-25 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating N-glycans
AU2008337304A1 (en) 2007-12-14 2009-06-25 Generics [Uk] Limited HPLC method for analysing clopidogrel
AU2009223014A1 (en) 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
US20110263649A1 (en) 2008-11-03 2011-10-27 Generics [Uk] Limited Crystalline form of lenalidomide and a process for its preparation
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide

Also Published As

Publication number Publication date
CN102414196A (zh) 2012-04-11
ES2487215T3 (es) 2014-08-20
SI2403845T1 (sl) 2014-09-30
SMT201400100B (it) 2014-11-10
US8946265B2 (en) 2015-02-03
CA2753241A1 (en) 2010-09-10
NZ595492A (en) 2013-07-26
HRP20140686T1 (hr) 2014-09-26
EP2403845B1 (en) 2014-04-30
EP2403845A2 (en) 2012-01-11
AU2010220204A1 (en) 2011-10-20
CA2753241C (en) 2015-06-16
CY1115376T1 (el) 2017-01-04
PT2403845E (pt) 2014-08-04
JP2012519207A (ja) 2012-08-23
PL2403845T3 (pl) 2014-09-30
US20120071509A1 (en) 2012-03-22
AU2010220204B2 (en) 2015-10-08
WO2010100476A3 (en) 2011-06-16
DK2403845T3 (da) 2014-08-04
WO2010100476A2 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
JP2012519207A (ja) 改良プロセス
JP6609065B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミンの新規な酸付加塩
JP7734700B2 (ja) ベータアドレナリンアゴニストの形態及び組成物
KR20090048364A (ko) 아고멜라틴의 결정형 ⅵ, 이의 제조 방법 및 이를 함유하는약제학적 조성물
US20110263649A1 (en) Crystalline form of lenalidomide and a process for its preparation
JP5086069B2 (ja) 重硫酸アタザナビルおよび新規形態の製造方法
JP6554617B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミン塩の新規な結晶形
US11739057B2 (en) Polymorphic forms of Belinostat and processes for preparation thereof
JP2014510139A (ja) 固体形態のｈｉｖ阻害剤
FI110096B (fi) Menetelmä terapeuttisesti käyttökelpoisen kiteisen Tiagabine-hydrokloridimonohydraatin valmistamiseksi
JP2017061578A (ja) 有機化合物
JP6644685B2 (ja) ポマリドミドの調製およびその精製のための改善された方法
JP2011529480A (ja) ラサジリンメシレートの多型
CN100384844C (zh) 黄嘌呤磷酸二酯酶v抑制剂多晶型物
TWI445697B (zh) 塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式
TW201546045A (zh) 新穎結晶性芳烷基胺化合物及其製造方法
US7041679B2 (en) Crystalline forms of osanetant
US20080004313A1 (en) Preparation of crystalline polymorphs of rimonabant hydrochloride
US20240327374A1 (en) Lenalidomide process
EP2765131B1 (en) Process for the production of Moxonidine
HK40129301A (zh) 盐酸替洛利生的多晶型形式
EP2177221A1 (en) Process for the preparation of substantially optically pure Repaglinide and precursors thereof
JP2010180169A (ja) アミド化合物の結晶

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150403

R150 Certificate of patent or registration of utility model

Ref document number: 5727944

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees